Literature DB >> 17911264

Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development.

Meritxell Gironella1, Mylène Seux, Min-Jue Xie, Carla Cano, Richard Tomasini, Julien Gommeaux, Stephane Garcia, Jonathan Nowak, Man Lung Yeung, Kuan-Teh Jeang, Amandine Chaix, Ladan Fazli, Yoshiharu Motoo, Qing Wang, Palma Rocchi, Antonio Russo, Martin Gleave, Jean-Charles Dagorn, Juan L Iovanna, Alice Carrier, Marie-Josèphe Pébusque, Nelson J Dusetti.   

Abstract

Pancreatic cancer is a disease with an extremely poor prognosis. Tumor protein 53-induced nuclear protein 1 (TP53INP1) is a proapoptotic stress-induced p53 target gene. In this article, we show by immunohistochemical analysis that TP53INP1 expression is dramatically reduced in pancreatic ductal adenocarcinoma (PDAC) and this decrease occurs early during pancreatic cancer development. TP53INP1 reexpression in the pancreatic cancer-derived cell line MiaPaCa2 strongly reduced its capacity to form s.c., i.p., and intrapancreatic tumors in nude mice. This anti-tumoral capacity is, at least in part, due to the induction of caspase 3-mediated apoptosis. In addition, TP53INP1(-/-) mouse embryonic fibroblasts (MEFs) transformed with a retrovirus expressing E1A/ras(V12) oncoproteins developed bigger tumors than TP53INP1(+/+) transformed MEFs or TP53INP1(-/-) transformed MEFs with restored TP53INP1 expression. Finally, TP53INP1 expression is repressed by the oncogenic micro RNA miR-155, which is overexpressed in PDAC cells. TP53INP1 is a previously unknown miR-155 target presenting anti-tumoral activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17911264      PMCID: PMC2042180          DOI: 10.1073/pnas.0703942104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma.

Authors:  Markus Metzler; Monika Wilda; Kerstin Busch; Susanne Viehmann; Arndt Borkhardt
Journal:  Genes Chromosomes Cancer       Date:  2004-02       Impact factor: 5.006

Review 2.  Intraductal papillary mucinous tumors of the pancreas.

Authors:  Kevin C Conlon
Journal:  J Clin Oncol       Date:  2005-07-10       Impact factor: 44.544

Review 3.  Molecular markers of early pancreatic cancer.

Authors:  Michael Goggins
Journal:  J Clin Oncol       Date:  2005-07-10       Impact factor: 44.544

Review 4.  A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes.

Authors:  O A Kent; J T Mendell
Journal:  Oncogene       Date:  2006-10-09       Impact factor: 9.867

Review 5.  MicroRNAs in biological processes and carcinogenesis.

Authors:  Hirotaka Osada; Takashi Takahashi
Journal:  Carcinogenesis       Date:  2006-10-06       Impact factor: 4.944

6.  Colitis and colitis-associated cancer are exacerbated in mice deficient for tumor protein 53-induced nuclear protein 1.

Authors:  Julien Gommeaux; Carla Cano; Stéphane Garcia; Meritxell Gironella; Sylvia Pietri; Marcel Culcasi; Marie-Josèphe Pébusque; Bernard Malissen; Nelson Dusetti; Juan Iovanna; Alice Carrier
Journal:  Mol Cell Biol       Date:  2007-01-22       Impact factor: 4.272

7.  Pancreatic intraepithelial neoplasia.

Authors:  Kyoichi Takaori; Ralph H Hruban; Anirban Maitra; Nobuhiko Tanigawa
Journal:  Pancreas       Date:  2004-04       Impact factor: 3.327

Review 8.  An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms.

Authors:  Ralph H Hruban; Kyoichi Takaori; David S Klimstra; N Volkan Adsay; Jorge Albores-Saavedra; Andrew V Biankin; Sandra A Biankin; Carolyn Compton; Noriyoshi Fukushima; Toru Furukawa; Michael Goggins; Yo Kato; Gunter Klöppel; Daniel S Longnecker; Jutta Lüttges; Anirban Maitra; G Johan A Offerhaus; Michio Shimizu; Suguru Yonezawa
Journal:  Am J Surg Pathol       Date:  2004-08       Impact factor: 6.394

9.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

10.  Intraductal papillary-mucinous neoplasm of the pancreas. The findings and limitations of cytologic samples obtained by endoscopic ultrasound-guided fine-needle aspiration.

Authors:  Edward B Stelow; Michael W Stanley; Ricardo H Bardales; Shawn Mallery; Rebecca Lai; Bradley M Linzie; Stefan E Pambuccian
Journal:  Am J Clin Pathol       Date:  2003-09       Impact factor: 2.493

View more
  238 in total

1.  Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation.

Authors:  Zhong-Bo Han; Hong-Yuan Chen; Jun-Wei Fan; Jun-Yi Wu; Hua-Mei Tang; Zhi-Hai Peng
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-10       Impact factor: 4.553

Review 2.  Implication of microRNAs in drug resistance for designing novel cancer therapy.

Authors:  Fazlul H Sarkar; Yiwei Li; Zhiwei Wang; Dejuan Kong; Shadan Ali
Journal:  Drug Resist Updat       Date:  2010-03-17       Impact factor: 18.500

3.  Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis.

Authors:  Xiangyu Kong; Yiqi Du; Guokun Wang; Jun Gao; Yanfang Gong; Lei Li; Zhuo Zhang; Jiaqi Zhu; Qing Jing; Yongwen Qin; Zhaoshen Li
Journal:  Dig Dis Sci       Date:  2010-07-08       Impact factor: 3.199

Review 4.  Cancer stem cells: involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics.

Authors:  Cristiana Pistol Tanase; Ana Iulia Neagu; Laura Georgiana Necula; Cristina Mambet; Ana-Maria Enciu; Bogdan Calenic; Maria Linda Cruceru; Radu Albulescu
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

5.  Pax-5 Inhibits NF-κB Activity in Breast Cancer Cells Through IKKε and miRNA-155 Effectors.

Authors:  Jason Harquail; Nicolas LeBlanc; Carine Landry; Nicolas Crapoulet; Gilles A Robichaud
Journal:  J Mammary Gland Biol Neoplasia       Date:  2018-07-21       Impact factor: 2.673

6.  Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile.

Authors:  Johan H Gibcus; Lu Ping Tan; Geert Harms; Rikst Nynke Schakel; Debora de Jong; Tjasso Blokzijl; Peter Möller; Sibrand Poppema; Bart-Jan Kroesen; Anke van den Berg
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

7.  Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers.

Authors:  Pradeep Chaluvally-Raghavan; Fan Zhang; Sunila Pradeep; Mark P Hamilton; Xi Zhao; Rajesha Rupaimoole; Tyler Moss; Yiling Lu; Shuangxing Yu; Chad V Pecot; Miriam R Aure; Sylvain Peuget; Cristian Rodriguez-Aguayo; Hee-Dong Han; Dong Zhang; Avinashnarayan Venkatanarayan; Marit Krohn; Vessela N Kristensen; Mihai Gagea; Prahlad Ram; Wenbin Liu; Gabriel Lopez-Berestein; Philip L Lorenzi; Anne-Lise Børresen-Dale; Koei Chin; Joe Gray; Nelson J Dusetti; Sean E McGuire; Elsa R Flores; Anil K Sood; Gordon B Mills
Journal:  Cancer Cell       Date:  2014-12-08       Impact factor: 31.743

8.  microRNA-155 acts as an oncogene by targeting the tumor protein 53-induced nuclear protein 1 in esophageal squamous cell carcinoma.

Authors:  Jie Zhang; Chen Cheng; Xiang Yuan; Jiang-Tu He; Qiu-Hui Pan; Fen-Yong Sun
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

Review 9.  MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications.

Authors:  Satyanarayana Rachagani; Sushil Kumar; Surinder K Batra
Journal:  Cancer Lett       Date:  2009-12-09       Impact factor: 8.679

10.  The role of microRNAs in gastrointestinal cancers.

Authors:  Yoshimasa Saito; Hidekazu Suzuki; Toshifumi Hibi
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.